ASCO 2023 | What are the latest in ADCs for prostate and bladder cancer?

Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, provides an overview of the latest updates in antibody-drug conjugates (ADCs) in genitourinary cancers. Despite the meagre progress in prostate cancer; PSMA and B7-H3 have been identified as potential targets, especially if a microtubule disruptor such as enfortumab vedotin is utilized. Findings from the EV-103 trial (NCT03288545) of enfortumab vedotin and pembrolizumab have displayed promising results in urothelial cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.